Treat and Trade: The New Priority Review Voucher Market
This article was originally published in RPM Report
Executive Summary
Starting in September, pharmaceutical companies will have the opportunity to buy the right to a faster FDA review on the open market. If it works, the priority review voucher program could revolutionize development of drugs for neglected diseases, while increasing the value of more traditional commercial products in the US.